SCHEMBL15031985

SCHEMBL15031985

Cc1ccccc1-c1n[nH]c(=O)c2cc(Br)ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 2/20 0.53
WDR77 Q9BQA1 2/20 0.53
LMNA P02545 1/20 0.46
TSHR P16473 1/20 0.46
ATM Q13315 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
DCLK1 O15075 1/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
CHEK2 O96017 1/20 0.42
CSF1R P07333 1/20 0.42
FER P16591 1/20 0.42
CDK2 P24941 1/20 0.42
MARK3 P27448 1/20 0.42
FLT4 P35916 1/20 0.42
FLT3 P36888 1/20 0.42
MAPK9 P45984 1/20 0.42
CSNK1D P48730 1/20 0.42
CLK2 P49760 1/20 0.42
CSNK2A1 P68400 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15010041 0.83 PDE4A (0.52) PRMT5WDR77TSHRATMNPSR1
SCHEMBL15031924 0.81 SCN9A (0.44) PRMT5WDR77LMNATSHRROCK1
SCHEMBL23526034 0.76 PRMT5 (0.49) PRMT5WDR77LMNAPRKD3MAP4K4
SCHEMBL29945916 0.76 PRMT5 (0.49) PRMT5WDR77LMNAPRKD3MAP4K4
SCHEMBL15031982 0.75 PRMT5 (0.46) PRMT5WDR77LMNATSHRATM
SCHEMBL8551285 0.75 AR (0.42) PRMT5WDR77LMNATSHRATM
SCHEMBL31014281 0.75 NPSR1 (0.67) PRMT5WDR77LMNATSHRATM
SCHEMBL8548318 0.74 AR (0.46) PRMT5WDR77LMNATSHRATM
SCHEMBL1789688 0.72 LMNA (0.59) LMNATSHRATMNPSR1ROCK1
SCHEMBL30719643 0.72 LMNA (0.59) LMNATSHRATMNPSR1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012443-B2 Bicyclic aryl and heteroaryl sodium channel inhibitors AMGEN INC. (US) 2015-04-21 US disclosed
US-20130150339-A1 Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors AMGEN INC. (US) 2013-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150339-A1 Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors SCN1A, SCN1B, CACNA1B PRMT5 4120/4885WDR77 2974/4885LMNA 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.